Shanghai Oricell Therapeutics

Oricell Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on developing innovative cell and gene therapies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary technology platforms—OriAb, OriCAR, OriTIL, and OriUCAR—to engineer next-generation CAR-T therapies designed for improved persistence and efficacy, particularly in solid tumors. Its lead candidate, ORI-C101, targets GPC3 for hepatocellular carcinoma and has demonstrated promising clinical data in early trials. Oricell maintains integrated capabilities spanning discovery, clinical development, and GMP-compliant manufacturing to accelerate its pipeline of treatments for both hematological and solid malignancies.